187 related articles for article (PubMed ID: 32016470)
1. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance.
Ou L; He X; Liu N; Song Y; Li J; Gao L; Huang X; Deng Z; Wang X; Lin S
Mol Med Rep; 2020 Mar; 21(3):1449-1460. PubMed ID: 32016470
[TBL] [Abstract][Full Text] [Related]
2. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
Liu N; Zhu M; Linhai Y; Song Y; Gui X; Tan G; Li J; Liu Y; Deng Z; Chen X; Wang J; Jia L; He X; Wang X; Lin S
Oncol Rep; 2018 Nov; 40(5):2997-3005. PubMed ID: 30226606
[TBL] [Abstract][Full Text] [Related]
3. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
4. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
5. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
6. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor.
Holdbrooks AT; Britain CM; Bellis SL
J Biol Chem; 2018 Feb; 293(5):1610-1622. PubMed ID: 29233887
[TBL] [Abstract][Full Text] [Related]
7. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
8. The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.
Schultz MJ; Holdbrooks AT; Chakraborty A; Grizzle WE; Landen CN; Buchsbaum DJ; Conner MG; Arend RC; Yoon KJ; Klug CA; Bullard DC; Kesterson RA; Oliver PG; O'Connor AK; Yoder BK; Bellis SL
Cancer Res; 2016 Jul; 76(13):3978-88. PubMed ID: 27216178
[TBL] [Abstract][Full Text] [Related]
9. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
10. Expression of N-Acetylglucosaminyltransferase III Suppresses α2,3-Sialylation, and Its Distinctive Functions in Cell Migration Are Attributed to α2,6-Sialylation Levels.
Lu J; Isaji T; Im S; Fukuda T; Kameyama A; Gu J
J Biol Chem; 2016 Mar; 291(11):5708-5720. PubMed ID: 26801611
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.
Cole C; Lau S; Backen A; Clamp A; Rushton G; Dive C; Hodgkinson C; McVey R; Kitchener H; Jayson GC
Cancer Biol Ther; 2010 Sep; 10(5):495-504. PubMed ID: 20595807
[TBL] [Abstract][Full Text] [Related]
12. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
Yuan Q; Chen X; Han Y; Lei T; Wu Q; Yu X; Wang L; Fan Z; Wang S
Int J Cancer; 2018 Nov; 143(9):2319-2330. PubMed ID: 29981167
[TBL] [Abstract][Full Text] [Related]
13. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.
Swindall AF; Bellis SL
J Biol Chem; 2011 Jul; 286(26):22982-90. PubMed ID: 21550977
[TBL] [Abstract][Full Text] [Related]
14. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
15. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
[TBL] [Abstract][Full Text] [Related]
16. ST6Gal-I regulates macrophage apoptosis via α2-6 sialylation of the TNFR1 death receptor.
Liu Z; Swindall AF; Kesterson RA; Schoeb TR; Bullard DC; Bellis SL
J Biol Chem; 2011 Nov; 286(45):39654-62. PubMed ID: 21930713
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
18. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
20. The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.
Britain CM; Dorsett KA; Bellis SL
J Biol Chem; 2017 Mar; 292(11):4663-4673. PubMed ID: 28154177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
